AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 52 min read$BBNX

Hopman Mark sold $3K of BBNX

Hopman Mark (Chief Commercial Officer) sold 275 shares of Beta Bionics, Inc. (BBNX) at $12.31 on 2026-06-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Hopman Mark
Published Jun 5, 2026, 10:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 5, 2026, 10:06 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$BBNX
Neutral
medium confidence
Mentioned
$BBNX
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BBNXNeutralLow
01

Why it matters

The disclosure may slightly pressure sentiment, but the 10b5-1 structure suggests the trade was scheduled rather than news-driven.

02

Market read

A routine 10b5-1 insider sale can be a minor sentiment headwind, with limited fundamental implications absent additional company news.

03

What to watch

Share count sold is small relative to holdings (275 shares vs 130,612 after), so the economic signal is likely limited.

Relevance 6/10Novelty 4/10Timing: SEC Form 4 filed today; sale occurred 2026-06-04

Background

This is an SEC Form 4 insider transaction (officer/direct holding) for Beta Bionics, Inc.

Company-level read

Ticker impact

$BBNXNeutralMedium confidence
Context

Beta Bionics CCO Hopman Mark sold 275 shares in an open-market transaction disclosed on SEC Form 4.

Expected impact

Likely limited/short-lived impact; watch for follow-through only if selling accelerates or is not clearly routine.

Evidence & confidence

The filing specifies an open-market sale and a pre-arranged Rule 10b5-1 plan, which reduces the likelihood of immediate new fundamental information.

Market effects

Sector

Adds a datapoint on insider behavior in small-cap biotech, but no direct read-across catalyst is provided.

Regional

None indicated beyond company-specific sentiment.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, the market may overreact; price impact could be negligible.

Key entities

  • issuer
    Beta Bionics, Inc.

    Subject of the SEC Form 4 insider sale by its Chief Commercial Officer.

  • insider
    Hopman Mark

    Chief Commercial Officer who sold 275 shares at $12.31 on 2026-06-04 under a 10b5-1 plan.

Read at source← All news

Related articles

JUL 29
$BBNXMedAI 8/10

Beta Bionics posts Q2 beats on 38% sales growth

Beta Bionics (Nasdaq:BBNX) reported Q2 results that beat consensus. For the quarter ended June 30, 2026, it posted a $23.4M loss (53¢/share) on $32.0M revenue, with sales up about 38% versus a year earlier. DME sales were $20.4M (+9%) and PBP sales $11.6M (+153%). It reaffirmed 2026 revenue guidance of $131M to $136M.

drugdeliverybusiness.com4 min
JUL 29
$BBNXMed

Beta Bionics (Nasdaq: BBNX) lifts Q2 sales to $32M amid ongoing losses

Beta Bionics (Nasdaq: BBNX) reported Q2 2026 net sales of $32.0M, up from $23.2M a year earlier, driven by its iLet insulin delivery device and single-use consumables. Six-month sales were $59.6M. The company reported a six-month net loss of $45.3M. As of June 30, 2026 it had $44.3M cash and $180.8M in U.S. Treasury investments, and an FDA Warning Letter in January 2026 cited quality system and reporting deficiencies.

stocktitan.net4 min
JUN 1
$BBNXMedAI 8/10

Robbins LLP is Investigating Allegations that the Officers and Directors of Beta Bionics, Inc. (BBNX) Violated Securities Laws and Breached Fiduciary Duties to Shareholders

Robbins LLP said it is investigating whether Beta Bionics Inc. (NASDAQ: BBNX) officers and directors violated securities laws or breached fiduciary duties. After Beta Bionics’ Jan. 8, 2026 preliminary Q4 2025 results, it expected at least 5,581 new patient starts (+36% YoY), below analyst expectations and down from the prior quarter’s 68% growth; the stock fell over 35% on Jan. 9.

wallstreet-online.de3 min